Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.

Shanghai Fudan Zhangjiang Biopharmaceutical Co. , Ltd. specializes in the research, development, manufacturing, and marketing of innovative pharmaceutical products aimed at addressing unmet medical needs in various therapeutic areas. Founded in 1996 and headquartered in Shanghai, China, Shanghai Fudan Zhangjiang Biopharmaceutical Co.

, Ltd. focuses on developing advanced therapeutics. The company has successfully completed 3 deals and recently raised USD 4. 40 mn in a PIPE funding round, with New Enterprise Capital as the investor.

The total amount raised by the company to date is USD 4. 40 mn. 上海复旦张江生物医药股份有限公司 (Fudan Zhangjiang) is dedicated to the research, development, manufacturing, and marketing of innovative pharmaceuticals. The company’s core products are advanced therapeutics designed for unmet medical needs, particularly in oncology and autoimmune disorders.

Fudan Zhangjiang utilizes technology to create novel compounds that improve treatment effectiveness and patient outcomes. Their offerings are targeted at healthcare providers, hospitals, and clinics, with a primary focus on the Chinese market and opportunities for expansion into Europe and North America. In 2021, 上海复旦张江生物医药股份有限公司 generated revenue of USD 176. 75 mn, alongside an EBITDA of USD 42.

03 mn. Revenue is derived from direct sales to healthcare organizations and strategic partnerships with pharmaceutical distributors, focusing on B2B transactions and structured agreements to meet client needs. Shanghai Fudan Zhangjiang Biopharmaceutical Co. , Ltd.

plans to continue expanding its product line with new therapeutics in development targeted for release in the next few years. The company aims to enter new markets, including specific expansions into Europe and North America by 2025. The recent funding from the PIPE round will be utilized to support these initiatives, enhancing product development and market outreach strategies.